Over the past 52 weeks, the shares of BorgWarner Inc. (NYSE:BWA) has been trading as low as $32.46 before witnessing a massive surge by 23.66% or $7.68. This price movement has led to the BWA stock receiving more attention and has become one to watch out for. It jumped by 3.4% on Tuesday and this got the market excited. The stock’s beta now stands at 1.75 and when compared to its 200-day moving average and its 50-day moving average, BWA price stands -6.32% below and 6.53% above respectively. Its average daily volatility for this week is 3.21% which is more than the 2.38% recorded over the past month. The shares of BorgWarner Inc. dropped by -26.15% or -$14.21 from its last recorded high of $54.35 which it attained on April 18 to close at $40.14 per share.
BorgWarner Inc. (BWA) sank -1.95% this week, a trend that has led to both investors and traders taking note of the stock. Over the past one year, the equity price has embarked on a drop that has seen it decline -23.7% and is now up by 15.54% since start of this year. A look at its monthly performance shows that the stock has recorded a 2.4% gain over the past 30 days. Its equity price dipped by 0% over the past three months which led to its overall six-month decrease to stand at -8.65%.
A look at BWA technical analysis shows that its 14-day Relative Strength Index (RSI) is in a neutral zone after reaching 55.54 point. Its trading volume has added 1040083 shares compared to readings over the past three months as it recently exchanged 2810083 shares. This means there is improved activity from short-term traders as per session, its average trading volume is 1770000 shares, and this is 1.59 times the normal volume.
Analysts have predicted a price target for Heron Therapeutics, Inc. (HRTX) for 1 year and it stands at an average $53.45/share. This means that it would likely increase by 91.58% from its current position. Some brokerage firms have a lower target for the stock than the average, with one of them setting a price target as low as $42. On the other hand, one analyst is super bullish about the price, setting a target as high as $76.
The HRTX stock Stochastic Oscillator (%D) is at 53.6%, which means that it is currently neutral. The shares P/S ratio stands at 36.67 which compares to the 50.73 recorded by the industry or the 9.79 by the wider sector. The stock currently has an estimated price-earnings (P/E) multiple of 0, which is lower than the 0 multiple of 12-month price-earnings (P/E). The company’s earnings have gone down, with a quarterly decrease rate of -12.8% over the past five years.
Analysts view Heron Therapeutics, Inc. (NASDAQ:HRTX) as a Buy, with 1.6 consensus rating. Reuters surveyed 11 analysts that follow HRTX and found that 0 of those analysts rated the stock as a Hold. The remaining 11 were divided, with 11 analyst rating it as a Buy or a Strong Buy while 0 analysts advised investors to desist from buying Heron Therapeutics, Inc. (HRTX) shares or sell it if they already own it.